专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060241121A1 Substituted piperazines as CB1 antagonists 失效
标题翻译：取代的哌嗪作为CB1拮抗剂
公开(公告)号：US20060241121A1
公开(公告)日：2006-10-26
申请号：US11292264
申请日：2005-12-01
申请人： William Greenlee , Jay Weinstein , Eric Gilbert , Michael Miller , Jack Scott , Andrew Stamford
发明人： William Greenlee , Jay Weinstein , Eric Gilbert , Michael Miller , Jack Scott , Andrew Stamford
IPC分类号： A61K31/496 , A61K31/495 , C07D403/04 , C07D241/04
CPC分类号： C07D241/04 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/08 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10
摘要： Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：式（I）化合物或其药学上可接受的盐，溶剂合物或酯可用于治疗由CB1受体介导的疾病或病症，例如代谢综合征和肥胖症，神经炎症性疾病，认知障碍精神病，成瘾（如戒烟），胃肠道疾病和心血管疾病。

2. 发明申请

US20070203183A1 Diaryl piperidines as CB1 modulators 审中-公开
标题翻译：二芳基哌啶作为CB1调节剂
公开(公告)号：US20070203183A1
公开(公告)日：2007-08-30
申请号：US11652227
申请日：2007-01-11
申请人： Jack Scott , Jay Weinstein , Michael Miller , Andrew Stamford , Eric Gilbert , Yan Xia , William Greenlee , Sarah Li
发明人： Jack Scott , Jay Weinstein , Michael Miller , Andrew Stamford , Eric Gilbert , Yan Xia , William Greenlee , Sarah Li
IPC分类号： A61K31/454 , C07D211/54 , A61K31/445 , C07D401/02
CPC分类号： C07D211/18 , C07D211/22 , C07D211/26 , C07D211/28 , C07D211/30 , C07D211/32 , C07D211/58 , C07D211/60 , C07D211/76 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D471/10
摘要： A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：具有式（I）的通式结构的化合物或其药学上可接受的盐，溶剂化物或酯可用于治疗疾病，病症或病症如代谢综合征（例如，肥胖，腰围，脂质分布和胰岛素敏感性），神经炎症性疾病，认知障碍，精神病，成瘾行为，胃肠道疾病和心血管疾病。

3. 发明申请

US20160009689A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY 有权
公开(公告)号：US20160009689A1
公开(公告)日：2016-01-14
申请号：US14772295
申请日：2014-02-27
申请人： Michael MILLER , Kallol BASU , Duane DEMONG , Jack SCOTT , Wei LI , Andrew STAMFORD , Marc POIRIER , Paul TEMPEST , MERCK SHARP & DOHME CORP.
发明人： Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Wei Li , Andrew Stamford , Marc Poirer , Paul Tempest
IPC分类号： C07D403/04 , C07D413/14 , C07D401/14 , C07D471/10 , C07D491/107 , C07D498/10 , C07D487/10 , C07D405/14 , C07D498/04 , C07D487/04 , C07D409/14 , C07D403/14 , C07D498/08
CPC分类号： C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/107 , C07D498/04 , C07D498/08 , C07D498/10
摘要： The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

4. 发明申请

US20160009696A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY 有权
公开(公告)号：US20160009696A1
公开(公告)日：2016-01-14
申请号：US14772290
申请日：2014-02-27
申请人： Michael MILLER , Kallol BASU , Duane DEMONG , Jack SCOTT , Wei LI , Joel HARRIS , Andrew STAMFORD , Marc POIRIER , Paul TEMPEST , MERCK SHARP & DOHME CORP.
发明人： Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Wei Li , Joel Harris , Andrew Stamford , Marc Poirier , Paul Tempest
IPC分类号： C07D403/14 , C07D401/14 , C07D491/107 , C07D417/14 , C07D471/10 , C07D413/14 , C07D498/08
CPC分类号： C07D403/14 , A61K31/505 , A61K31/506 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/10 , C07D491/107 , C07D498/08
摘要： The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

5. 发明申请

US20160009681A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY 有权
标题翻译：化合物抑制富含重复激素激酶活性
公开(公告)号：US20160009681A1
公开(公告)日：2016-01-14
申请号：US14772525
申请日：2014-02-27
申请人： Michael MILLER , Kallol BASU , Duane MONG , Jack SCOTT , Hong LIU , Xing DAI , Andrew STAMFORD , Marc POIRIER , Paul TEMPEST , MERCK SHARP & DOHME CORP.
发明人： Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Hong Liu , Xing Dai , Andrew Stamford , Marc Poirier , Paul Tempest
IPC分类号： C07D401/04 , C07D498/08 , C07D401/14 , C07D495/08 , C07D498/04 , C07D487/04 , C07D413/14 , C07D405/14 , C07D417/14
CPC分类号： C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D491/08 , C07D495/08 , C07D498/04 , C07D498/08
摘要： The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
摘要翻译：本发明涉及作为LRRK2激酶的有效抑制剂的吲唑化合物，可用于治疗或预防其中涉及LRRK2激酶的疾病，例如帕金森病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及LRRK2激酶的疾病中的用途。

6. 发明申请

US20070197628A1 Cannabinoid receptor modulators 失效
标题翻译：大麻素受体调节剂
公开(公告)号：US20070197628A1
公开(公告)日：2007-08-23
申请号：US11653558
申请日：2007-01-16
申请人： Samuel Chackalamannil , Mariappan Chelliah , Martin Clasby , Keith Eagen , Jack Scott , Yuguang Wang , Yan Xia , William Greenlee
发明人： Samuel Chackalamannil , Mariappan Chelliah , Martin Clasby , Keith Eagen , Jack Scott , Yuguang Wang , Yan Xia , William Greenlee
IPC分类号： A61K31/4035 , C07D209/46
CPC分类号： C07D209/46 , C07C233/31 , C07C233/58 , C07C233/59 , C07C233/60 , C07C233/90 , C07D209/44 , C07D209/52 , C07D211/58 , C07D307/83 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/10
摘要： A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.
摘要翻译：具有式（I）的通式结构的化合物或其药学上可接受的盐，溶剂化物或酯可用于治疗疾病，病症或病症如肥胖，代谢紊乱，成瘾，中枢神经系统疾病，心血管疾病，呼吸系统疾病和胃肠道疾病。

7. 发明申请

US20080095740A1 PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS 审中-公开
标题翻译：哌啶衍生物作为CCR5拮抗剂有用
公开(公告)号：US20080095740A1
公开(公告)日：2008-04-24
申请号：US11925119
申请日：2007-10-26
申请人： Michael Miller , Jack Scott
发明人： Michael Miller , Jack Scott
IPC分类号： A61K31/506 , A61K31/538 , A61K31/551 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K38/20 , A61P31/18
CPC分类号： C07D401/14
摘要： The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
摘要翻译：本发明提供下式的化合物或其药学上可接受的盐或溶剂合物，其中各种部分如说明书中所定义。本发明还提供含有本发明化合物的药物组合物和使用本发明化合物的治疗方法。本发明还涉及本发明化合物与一种或多种可用于治疗人类免疫缺陷病毒（HIV）的抗病毒剂或其它药剂的组合的用途。本发明还涉及本发明化合物单独或与另一种药剂组合用于治疗实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化。

8. 发明申请

US20060025441A1 Bipiperidinyl derivatives useful as inhibitors of chemokine receptors 失效
标题翻译：可用作趋化因子受体抑制剂的二哌啶基衍生物
公开(公告)号：US20060025441A1
公开(公告)日：2006-02-02
申请号：US10979075
申请日：2004-11-01
申请人： Michael Miller , Jack Scott
发明人： Michael Miller , Jack Scott
IPC分类号： A61K31/4545 , C07D401/04
CPC分类号： C07D413/14 , C07D401/14
摘要： In its many embodiments, the present invention provides a novel class of bipiperidinyl compounds as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
摘要翻译：在其许多实施方案中，本发明提供了作为CCR5受体的抑制剂的新类型的联哌啶化合物，制备这些化合物的方法，含有一种或多种这样的化合物的药物组合物，制备包含一种或多种这样的化合物的药物制剂的方法，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与CCR5相关的一种或多种疾病的方法。本发明还涉及本发明化合物与一种或多种可用于治疗人类免疫缺陷病毒（HIV）的抗病毒剂或其它药剂的组合的用途。本发明还涉及本发明化合物单独或与另一种药剂组合用于治疗实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化。

9. 发明授权

US06686027B1 Security substrate for documents of value 失效
标题翻译：安全基板的价值文件
公开(公告)号：US06686027B1
公开(公告)日：2004-02-03
申请号：US09669425
申请日：2000-09-25
申请人： Omar Caporaletti , John Nicholas Disano , Jack Scott
发明人： Omar Caporaletti , John Nicholas Disano , Jack Scott
IPC分类号： B32B2302
CPC分类号： B32B7/02 , B42D25/29 , Y10T428/24802 , Y10T428/31678 , Y10T428/31823 , Y10T428/31909
摘要： A security substrate for a document of value comprises a laminate including a generally transparent core layer and generally transparent outer layers on opposite sides of the core layer. At least one interference filter is embedded within the laminate. The interference filter includes a highly reflective opaque layer on a surface of the core layer and an optically variable thin film multilayer overlying at least a portion of the opaque layer. The interference filter is covered by one of the outer layers.
摘要翻译：用于文件证件的安全基板包括层叠体，其包括通常透明的芯层和在芯层的相对侧上的通常透明的外层。至少一个干涉滤光片嵌入层压板内。干涉滤光器包括在芯层的表面上的高反射不透明层和覆盖在不透明层的至少一部分上的光学可变薄膜多层。干涉滤光片被外层之一覆盖。

10. 发明申请

US20080081160A1 Ink Receptive Coatings For Woven and Nonwoven Substrates 审中-公开
标题翻译：用于编织和非织造基材的油墨接受涂层
公开(公告)号：US20080081160A1
公开(公告)日：2008-04-03
申请号：US11863339
申请日：2007-09-28
申请人： Gary Anderle , Jack Scott , Timothy Felmet
发明人： Gary Anderle , Jack Scott , Timothy Felmet
IPC分类号： B41M5/00 , C08G73/00 , C08J3/05
CPC分类号： B41M5/52 , B41M5/5218 , B41M5/5281 , C09D175/04 , D06P1/5285 , D06P5/30 , Y10T428/24802 , C08L2666/02
摘要： A print receptive polyurethane coating is described. It is derived from a non-ionically stabilized polyurethane dispersion and an ink receptive particulate. Coatings and films for textiles and other articles and applications using such polyurethanes have been described.
摘要翻译：描述了印刷接受性聚氨酯涂层。它衍生自非离子稳定的聚氨酯分散体和油墨接收颗粒。已经描述了使用这种聚氨酯的纺织品和其它制品和应用的涂料和薄膜。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式